CINN‑102
Alpha‑1 Antitrypsin Deficiency
PreclinicalActive
Key Facts
About Cinnagen
Cinnagen leverages a self‑amplifying mRNA platform to create durable, low‑dose therapeutics for rare diseases and cancer.
View full company profileAlpha‑1 Antitrypsin Deficiency
Cinnagen leverages a self‑amplifying mRNA platform to create durable, low‑dose therapeutics for rare diseases and cancer.
View full company profile